Biocryst Pharmaceuticals Inc.
NASDAQ:BCRX
Debt Financing / Related
BioCryst Announces $325 Million Of Funding From Royalty Pharma, Athyrium Capital Management
Published: 12/07/2020 13:56 GMT
Biocryst Pharmaceuticals Inc. (BCRX) - Biocryst Announces $325 Million of Funding From Royalty Pharma and Athyrium Capital Management.
Biocryst Pharmaceuticals - Royalty Pharma Will Receive Royalties of 8.75% on Direct Annual Net Sales of Orladeyo Up to $350 Million.
Biocryst - Royalty Pharma to Get Royalties of 2.75% on Annual Net Sales of Orladeyo Between $350 Million and $550 Million, No Royalty on Sales Over $550 Million.
Biocryst Pharmaceuticals Inc - Royalty Pharma Will Receive a 1.0% Royalty on Global Net Sales of Bcx9930, If Approved.
Biocryst Pharmaceuticals Inc - Fund Managed by Athyrium Capital Management Will Provide Co With a $200 Million Credit Facility.
Biocryst Pharmaceuticals Inc - Additional Capital Will Be Available in Two Tranches at Co's Option, Upon Reaching Defined Revenue Milestones.
Biocryst Pharmaceuticals - Royalty Pharma Will Receive Royalties of 8.75% on Direct Annual Net Sales of Orladeyo Up to $350 Million.
Biocryst - Royalty Pharma to Get Royalties of 2.75% on Annual Net Sales of Orladeyo Between $350 Million and $550 Million, No Royalty on Sales Over $550 Million.
Biocryst Pharmaceuticals Inc - Royalty Pharma Will Receive a 1.0% Royalty on Global Net Sales of Bcx9930, If Approved.
Biocryst Pharmaceuticals Inc - Fund Managed by Athyrium Capital Management Will Provide Co With a $200 Million Credit Facility.
Biocryst Pharmaceuticals Inc - Additional Capital Will Be Available in Two Tranches at Co's Option, Upon Reaching Defined Revenue Milestones.